Literature DB >> 11059749

Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.

X Zi1, J Zhang, R Agarwal, M Pollak.   

Abstract

Silibinin, a naturally occurring flavonoid antioxidant found in the milk thistle, has recently been shown to have potent antiproliferative effects against various malignant cell lines, but the underlying mechanism of action remains to be elucidated. We investigated the effect of silibinin on androgen-independent prostate cancer PC-3 cells. At pharmacologically achievable silibinin concentrations (0.02-20 microM), we observed increased insulin-like growth factor-binding protein 3 (IGFBP-3) accumulation in PC-3 cell conditioned medium and a dose-dependent increase of IGFBP-3 mRNA abundance with a 9-fold increase over baseline at 20 microM silibinin. An IGFBP-3 antisense oligodeoxynucleotide that attenuated silibinin-induced IGFBP-3 gene expression and protein accumulation reduced the antiproliferative action of silibinin. We also observed that silibinin reduced insulin receptor substrate 1 tyrosine phosphorylation, indicating an inhibitory effect on the insulin-like growth factor I receptor-mediated signaling pathway. These results suggest a novel mechanism by which silibinin acts as an antiproliferative agent and justify further work to investigate potential use of this compound or its derivatives in prostate cancer treatment and prevention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Authors:  Deepali Sachdev; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

2.  Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.

Authors:  Rana P Singh; Komal Raina; Girish Sharma; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 3.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

4.  Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells.

Authors:  Vandanajay Bhatia; Miriam Falzon
Journal:  Cancer Lett       Date:  2015-04-03       Impact factor: 8.679

Review 5.  Complementary and alternative medicines in prostate cancer: from bench to bedside?

Authors:  Samuel J Klempner; Glenn Bubley
Journal:  Oncologist       Date:  2012-05-22

6.  WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.

Authors:  Yaxiong Tang; Anne R Simoneau; Wu-xiang Liao; Guo Yi; Christopher Hope; Feng Liu; Shunqiang Li; Jun Xie; Randall F Holcombe; Frances A Jurnak; Dan Mercola; Bang H Hoang; Xiaolin Zi
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

Review 7.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

8.  Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.

Authors:  Rana P Singh; Komal Raina; Gagan Deep; Daniel Chan; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

Review 10.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.